Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

Stock Performance - Amgen's stock ended the recent trading session at $277 88, showing a +1 62% increase from the previous day's closing price [1] - The stock outperformed the S&P 500, which gained 0 53%, while the Dow gained 0 93% and the Nasdaq added 0 22% [1] - Over the past month, Amgen's shares gained 3 38%, outperforming the Medical sector's 1 49% gain and the S&P 500's 2 69% gain [1] Earnings and Revenue Projections - Amgen's upcoming earnings report is scheduled for February 4, 2025, with projected earnings per share (EPS) of$ 5 01, reflecting a 6 37% increase from the same quarter last year [2] - Revenue is expected to be $8 84 billion, indicating a 7 86% increase compared to the same quarter of the previous year [2] Analyst Estimates and Valuation Metrics - Recent shifts in analyst projections for Amgen indicate changing near-term business trends, with upbeat changes reflecting a favorable outlook on the company's business health and profitability [3] - The Zacks Consensus EPS estimate has moved 0 43% higher within the past month, and Amgen currently holds a Zacks Rank 3 (Hold) [5] - Amgen's Forward P/E ratio is 13 36, representing a discount compared to the industry average of 23 22 [6] - The company's PEG ratio is 2 78, higher than the industry average of 1 36, reflecting its expected earnings growth trajectory [7] Industry Performance - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 74, placing it in the top 30% of all 250+ industries [8] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]